- Home
- ERAS vs FULT Comparison
ERAS vs FULT Comparison
Compare ERAS & FULT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ERAS | FULT |
|---|---|---|
| Founded | 2018 | 1882 |
| Country | United States | United States |
| Employees | N/A | 3400 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.1B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ERAS | FULT |
|---|---|---|
| Price | $17.72 | $24.18 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 4 |
| Target Price | $14.25 | ★ $21.75 |
| AVG Volume (30 Days) | ★ 5.6M | 2.1M |
| Earning Date | 05-08-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 3.55% |
| EPS Growth | ★ 36.23 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.39 |
| Revenue Next Year | N/A | $5.52 |
| P/E Ratio | ★ N/A | $10.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $16.60 |
| 52 Week High | $24.28 | $24.71 |
Technical Indicators
Market Signals| Indicator | ERAS | FULT |
|---|---|---|
| Relative Strength Index (RSI) | 59.88 | 61.46 |
| Support Level | $12.36 | $21.68 |
| Resistance Level | $18.20 | $24.71 |
| Average True Range (ATR) | 1.17 | 0.47 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 58.53 | 69.36 |
Price Performance
Historical ComparisonAbout ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
About FULT Fulton Financial Corporation
Fulton Financial Corp is a U.S.-based financial services holding company that operates in five states: Pennsylvania, Delaware, Maryland, New Jersey and Virginia. It offers a range of consumer and commercial banking products and services, such as checking and savings deposit products and loan products. It offers consumer and commercial banking products and services, as well as wealth management products and services. The bank derives its revenue from non-interest income, led by its Wealth Management division.